Trying to avoid a CRL? New FDA draft guidance talks benefit-risks on quality assessments
As manufacturing-related issues continue to plague the biopharma industry and lead to dozens or more FDA rejections, or CRLs, each year, the agency on Monday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
